Background: The World Health Organization recommends that antiretroviral therapy (ART)
programs in resource-limited settings develop third-line ART policies. South Africa …

Introduction: Despite the potency of current antiretrovirals, some patients continue to
struggle with the management of the treatment of HIV due to drug resistance-associated …

Background An increasing number of patients in Africa are experiencing virologic failure on
second-line antiretroviral therapy (ART) and those who develop resistance to protease …

Objective We evaluated the effectiveness of darunavir (DRV) treatment plus an optimized
background regimen in 120 HIV-1 treatment-experienced patients. Design Retrospective …

Background Development of drug-resistance mutations is the main cause of failure in
antiretroviral therapy. In Brazil, there is scarce information on resistance pattern for patients …

Background: The clinical and demographic characteristics that predict antiretroviral efficacy
among patients co-infected with HIV and hepatitis B virus (HBV) remain poorly defined. We …

Even though darunavir/ritonavir (DRV/r) has high potency and a greater genetic barrier,
there are few studies on the long-term effectiveness of DRV/r-based salvage therapy in …

Antiretroviral therapy has significantly evolved in the last decade, with an increasing number
of new drugs and classes. Currently, even heavily experienced patients can be successfully …

The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was
retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral …

Management of highly antiretroviral therapy(ART)-experienced patients continues to be a
challenge, and there are scarce “real-world” data about their long-term virologic and …